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Exogenously  administered  B-type  natriuretic  peptide  (BNP)  has  been  shown  to  offer  cardioprotection
through  activation  of  particulate  guanylyl  cyclase  (pGC),  protein  kinase  G (PKG)  and  KATP channel  opening.
The  current  study  explores  if cardioprotection  afforded  by  short  intermittent  BNP  administration  involves
PI3K/Akt/p70s6k  dependent  signaling,  and  whether  this  signaling  pathway  may  participate  in regulation
of  BNP  mRNA  expression  at early  reperfusion.  Isolated  Langendorff  perfused  rat  hearts  were  subjected
to  30  min  of  regional  ischemia  and  120 min  of reperfusion  (IR).  Applying  intermittent  3 × 30 s infusion  of
BNP  peptide  in  a postconditioning  like  manner  (BNPPost)  reduced  infarct  size  by  >50%  compared  to con-
trols  (BNPPost 17  ± 2%  vs. control  42  ±  4%,  p < 0.001).  Co-treatment  with  inhibitors  of the  PI3K/Akt/p70s6k
pathway  (wortmannin,  SH-6  and  rapamycin)  completely  abolished  the  infarct-limiting  effect  of  BNP
postconditioning  (BNPPost + Wi 36  ±  5%,  BNPPost +  SH-6  41  ±  4%,  BNPPost +  Rap 37 ± 6%  vs.  BNPPost 17 ±  2%,
p <  0.001).  Inhibition  of  natriuretic  peptide  receptors  (NPR)  by  isatin  also  abrogated  BNPPost cardioprotec-
tion  (BNPPost +  isatin  46  ± 2%  vs.  BNPPost 17  ± 2%,  p  < 0.001).  BNPPost also  signiﬁcantly  phosphorylated  Akt
and  p70s6k  at early  reperfusion,  and  Akt phosphorylation  was  inhibited  by SH-6 and  isatin.  Myocardial
BNP  mRNA  levels  in  the area  at risk (AA)  were  signiﬁcantly  elevated  at early  reperfusion  as  compared
to  the  non-ischemic  area  (ANA)  (Ctr(AA) 2.7  ±  0.5  vs.  Ctr(ANA) 1.2  ± 0.2,  p < 0.05)  and  the  ischemic  control
tissue  (Ctr(AA) 2.7 ±  0.5  vs.  ischemia  1.0  ± 0.1, p  <  0.05).  Additional  experiments  also  revealed  a  signiﬁcant
higher  BNP  mRNA  level  in ischemic  postconditioned  (IPost)  hearts  as compared  to  ischemic  controls
(IPost  6.7  ± 1.3  vs. ischemia  1.0  ± 0.2,  p < 0.05),  but  showed  no  difference  from  controls  run  in parallel
(Ctr  5.4  ± 0.8).  Akt  inhibition  by SH-6  completely  abrogated  this  elevation  (IPost  6.7  ±  1.3  vs.  IPost  +  SH-
6  1.8  ±  0.7,  p <  0.05)  (Ctr  5.4 ±  0.8  vs.  SH-6  1.5  ±  0.9,  p < 0.05).  In conclusion,  Akt  dependent  signaling  is
involved  in mediating  the  cardioprotection  afforded  by intermittent  BNP  infusion  at  early  reperfusion,
and  may  also  participate  in  regulation  of reperfusion  induced  BNP  expression.
©  2015  The  Authors.  Published  by Elsevier  Inc. This  is an  open  access  article  under  the CC  BY-NC-NDntroduction
The polypeptide hormone brain natriuretic peptide (BNP) is
art of the cardiac natriuretic peptide (NP) family, comprising
trial (ANP), BNP and C-type natriuretic peptide (CNP) [1–6]. Until
ecently, BNP release was solely believed be caused by ventricu-
ar wall distension, but accumulating evidence support ischemia
7] and hypoxia [8] to be independent triggers of BNP release.
urthermore, exogenous administered BNP can reduce injuries
ssociated with ischemia reperfusion in the isolated heart [9–13].
∗ Corresponding author.
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This BNP mediated cardioprotection appears to be mediated via the
natriuretic peptide receptor type A (NPR-A) [14], activating a cGMP-
dependent protein kinase G (PKG) [15] that further modulates
opening of mitochondrial and sarcolemmal KATP channels (mKATP
and sKATP) and endogenous nitric oxide synthase (eNOS) [9]. How-
ever, activation of other signaling pathways also appears pivotal in
NP induced cardioprotection, as ANP administration just prior to
reperfusion limited infarct size in rabbit hearts, a protection that
was lost when inhibiting either NPR-A, PI3K (phosphatidylinositol
3-kinase), ERK (extracellular signal-regulated kinase), or mKATP
channels [16]. PI3K is part of the cytoprotective reperfusion injury
salvage kinases signaling pathway (RISK) that downstream phos-
phorylates Akt and p70S6k [17]. Currently, however, it is unknown
whether exogenously administered BNP may  activate Akt depend-
ent RISK signaling in the isolated rat heart at reperfusion.
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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BNP is considered to be an immediate-early gene that has proven
o be both rapidly synthesized and released (within 1 h) in response
o ischemia in vivo [18] and after reoxygenation in the ex vivo per-
used rat heart [8,11]. Recently, it has also been suggested that
schemia-reperfusion (IR) may  lead to increased myocardial BNP
RNA independently of changes in ventricular function [19]. Sci-
ntiﬁc evidence also suggests that natriuretic peptides (NPs) may
erve as autacoid mediators of ischemic postconditioning (IPost),
ince the natriuretic peptide receptor inhibitor isatin abolished the
Post induced protection [9]. It is well known that IPost mediates it
ardioprotective effect via Akt-dependent RISK signaling. Akt par-
icipates in gene transcription regulation [20–23] and activated
ucleus localized Akt has been shown to enhance ANP expression
24]. The relationship between myocardial reperfusion and BNP
ynthesis has yet to be fully established, and it is unknown whether
kt may  participate in regulation of myocardial BNP expression
evel at early reperfusion.
The objectives of this study were to: (1) study if intermittent
xogenous BNP administration may  mimic  IPost induced cardio-
rotection, (2) investigate if this cardioprotection is mediated via
kt and NPR dependent signaling, (3) explore how early BNP mRNA
xpression alters at reperfusion after an acute myocardial ischemic
vent, and (4) delineate whether Akt dependent signaling may  reg-
late reperfusion induced BNP expression.
aterials and methods
angendorff perfusion
All experiments were approved by the Norwegian State Com-
ission for Laboratory Animals, and carried out in accordance
ith the European Communities Council Directive (2010/63/EU).
emale Wistar rats (n = 114, 200–300 g) were heparinized (200 IU)
nd anesthetized with sodium pentobarbital (50 mg/kg) ip. After
xcision, the heart was immediately placed in Krebs Henseleit
uffer (KHB, 4 ◦C), and rapidly mounted in Langendorff perfusion
odus at constant pressure (80 mmHg). The KH-buffer contained:
aCl (118 mM),  NaHCO3 (25 mM),  KCl (4.7 mM),  MgSO4 × 7 H2O
1.22 mM),  KH2PO4 (1.21 mM),  d-glucose (11 mM),  CaCl2 × 2 H2O
1.8 mM)  (pH 7.4, oxygenated with 95% O2 and 5% CO2). Coronary
ow (CF in ml/min) was measured by timed collection of coronary
fﬂuent, and a thermo-probe placed in the pulmonary artery mon-
tored the cardiac temperature (kept at ∼37 ◦C). A 3-0 silk suture
as passed around the main branch of the left coronary artery,
nd threaded through a small vinyl tube to form a snare. Regional
schemia (RI) was  achieved by pulling the snare, and conﬁrmed by
 substantial fall in left ventricular developed pressure (LVDP) and
F. Reperfusion was achieved by releasing the snare.
easurement of ischemic risk zone and infarct size
The silk suture was securely tightened at the end of each experi-
ent and a 0.2% (w/v) Evans Blue suspension infused to demarcate
he risk zone (Duke Scientiﬁc Corp., Palo Alto, CA, USA). Thereafter,
he hearts were frozen (−20 ◦C) and later cut into 2-mm thick slices
rom apex to basis of the heart, and stained with 1% triphenylte-
razolium chloride (TTC) in phosphate buffer (pH 7.4) at 37 ◦C for
0 min, before ﬁxation in 4% formalin to enhance the contrast of the
tain. The area of the left ventricle, the infarcted area (TTC negative)
nd the risk zone (not blue) were determined using a computerized
lanimetry program (Planimetry+ v2.0; ENK, Norway) and infarct
ize expressed as the infarct/risk ratio (%). The coefﬁcient of vari-
tion (CV) for the area at risk/left ventricle volume ratio (AAR/LV)
ere 28%. 66 (2015) 43–50
Experimental protocol for the ex vivo rat heart
Three sets of perfusion experiments were performed: (1) infarct
size determination after intermittent BNP infusion, (2) heart perfu-
sions for tissue isolation to determine the effect of BNP treatment
on phosphorylation of Akt and p70s6k and (3) heart perfusions for
tissue isolation for investigation of BNP mRNA expression in the left
ventricle (LV). Infarct size determination: all hearts were stabilized
for 20 min  before being subjected to 30 min  regional ischemia and
120 min  reperfusion (Fig. 1). Rat BNP (10 nM) (Sigma–Aldrich) [11]
was administered in a postconditioning like manner for 3 × 30 s
at immediate ischemia-reperfusion (BNPPost). To investigate the
role of pro-survival RISK signaling in BNPPost induced cardioprotec-
tion, the following inhibitors ± BNP treatment were administered
at ischemic reperfusion: PI3K inhibitor wortmannin (Wi; 1 M)
[25], Akt inhibitor SH-6 (SH-6; 10 M)  [26] and the mTOR/p70s6k
inhibitor rapamycin (Rap; 1 nM)  [25] (all from Calbiochem). The
effect of inhibiting the natriuretic peptide receptor (NPR) with
isatin (100 M)  [9] (Sigma) during BNP postconditioning was also
investigated. Tissue isolation for immunoblotting: tissue for deter-
mination of the phosphorylation status of Akt and p70s6k in the
LV were isolated at baseline and at 15 min  of reperfusion. Tissue
isolation for BNP mRNA expression analysis: tissue samples for
mRNA analysis were collected at end ischemia, at 15 and 120 min
into the ischemic-reperfusion period. Furthermore, in additional
experiments, tissue was  isolated from hearts exposed to ischemic
postconditioning (IPost; 3 × 30 s of global ischemia) and parallel
run controls at early reperfusion ± the Akt inhibitor SH-6.
Immunoblot analysis
Myocardial Akt (Phospho-Akt, Ser473) and p70s6 kinase phos-
phorylation (Phospho-p70s6k, Thr389) in the area at risk was
determined by SDS-PAGE electrophoresis (all antibodies from Cell
Signaling Technology, USA), and phosphorylation was  expressed as
the ratio between phosphorylated and total protein levels. Hearts
perfused with BNP for 10 min  (BNPB) or KH-buffer for 10 min
served as baseline controls (CtrB). Tissue was  collected at 15 min
of ischemia-reperfusion, snap frozen in liquid nitrogen and stored
at −80 ◦C. Homogenization, protein quantiﬁcation, sample prepara-
tion (40 g/lane) and electrophoresis were performed as previously
described [26]. Ponceau S staining (Sigma, St. Louis, USA) conﬁrmed
successful transfer and GAPDH conﬁrm equal loading (Santa Cruz
Biotechnology, CA, USA). Densitometric analysis was performed
using Quantity One software (Bio-Rad, CA, USA).
Real-time quantitative reverse transcriptase polymerase chain
reaction (qRT-PCR)
Area at risk (AA, ischemic tissue) and area non at risk (ANA,
non-ischemic tissue) were collected immediately after identiﬁca-
tion of area at risk by Evans Blue staining and stored in RNAlater
(Ambion) according to the manufacturer’s protocol. The cardiac
tissue was  homogenized in TRIzol (Invitrogen, 1 ml/100 mg  tis-
sue) in a Precellys 24 homogenizer (Bertin Technologies) using
ceramic beads CK28 (Bertin Technologies; two times at 6000 rpm
for 15 s separated with 30 s). After treatment with Recombinant
DNase I (Takara) and ammonium acetate precipitation (Ambion),
total RNA was further puriﬁed using RNeasy Mini Kit (Qiagen).
First strand cDNA was synthesized from 3 g total RNA in a 40 L
reaction primed with 600 ng oligo (dT12–18; Invitrogen) using 2 L
AfﬁnityScript (Stratagene). A standard curve with 0.1–10 g total
RNA was  made to control for reverse transcription and PCR quan-
tiﬁcation. Reactions without reverse transcriptase enzyme run in
parallel were negative when tested for presence of genomic DNA.
The synthesized cDNA was  diluted by adding 160 L RNase free
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Fig. 1. Experimental protocol. Isolated female rat hearts were mounted and retrogradely perfused with Krebs Heinsleit Buffer (KHB, solid lines) in a Langendorff perfusion
setup.  All hearts were subjected to 20 min  stabilization, 30 min  regional ischemia (RI) and 120 min  reperfusion. Solid lines = buffer perfusion; BNPPost = BNP postconditioning,
3  × 30 s of exogenous BNP infusion (10 nM). The PI3K inhibitor wortmannin (Wi, 1 M),  the Akt-inhibitor SH-6 (10 M),  the mTOR/p70s6k inhibitor rapamycin (Rap, 1 nM),
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nd  ischemia, at 15 and 120 min  into the ischemic-reperfusion period (indicated by
ater. BNP was quantiﬁed using Messagreen (Eurogentech) with
 l cDNA as template with 300 nM of each primer pair for the
atriuretic peptide precursor B (preproBNP, Nppb) [27] or GAPDH
28]. The qPCR was performed on a HTS 7900 (Applied Biosystem)
ith initial denaturation at 95 ◦C for 10 min  and the PCR cycled
t 95 ◦C for 1 s and 60 ◦C for 30 s (45 cycles) followed by a melt-
ng point analysis conﬁrming the primer speciﬁcity by detection
f one PCR product only. Ampliﬁcation efﬁciency for each qPCR
eaction was calculated from the slope of the standard curve [efﬁ-
iency = 10(−1/slope) − 1] and the standard curve method was  used
o calculate individual level for each mRNA analysed. The level of
ppb mRNA was analysed and expressed relative to the house-
eeping gene GAPDH. The mean of ischemic tissue prior at start of
eperfusion were assigned the value 1 to simplify comparison of
RNA.
tatistical analysisValues are presented as mean ± standard error of the mean
S.E.M.). Infarct size, AAR/LV, LVDP, HR, CF and SDS-PAGE elec-
rophoresis results were tested for group differences by one way
nalysis of variance (ANOVA) combined with the Bonferroni post
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ig. 2. Administration of BNP as a mimetic of postconditioning limits infarct size via PI3K/
ignaling such as the PI3K inhibitor Wortmannin (Wi, 1 M),  the Akt inhibitor SH-6 (10 
ize  sparing effect of BNPPost. Infarct size is expressed as a percentage of the area at risk. Bin  starting 1 min  prior to reperfusion Tissue isolation for immunoblotting: tissue
NP mRNA expression analysis: tissue samples for mRNA analysis were collected at
s).
hoc test. The BNP mRNA data were tested for group differences
by applying a Students t-test. A value of p < 0.05 was considered
statistically signiﬁcant.
Results
BNP postconditioning limits infarct size via PI3K/Akt/p70s6k
dependent signaling and natriuretic peptide receptor inhibition
Intermittent administration of BNP for 3 × 30 s at the imme-
diate onset of ischemic-reperfusion (BNPPost), to mimic ischemic
postconditioning, resulted in a >50% reduction in infarct size
as compared to the control group (BNPPost 17 ± 2% vs. control
42 ± 4%, p < 0.001) (Fig. 2). In order to determine the involve-
ment of PI3K/Akt/p70s6k dependent signaling afforded by BNP
postconditioning, three inhibitors of this pathway were utilized
(experimental protocol, Fig. 1). The PI3K-inhibitor Wi  (1 M),
Akt inhibitor SH-6 (10 M)  and the mTor/p70s6k-inhibitor Rap
(1 nM)  all completely abolished the effect of BNP postconditioning
(BNPPost + Wi  36 ± 5%, BNPPost + SH-6 41 ± 4%, BNPPost + Rap 37 ± 6%
vs. BNPPost 17 ± 2%, p < 0.001) (Fig. 2). Inhibitor administration
alone had no effect on infarct size (Wi  47 ± 2%, SH-6 39 ± 4%, Rap
BNPPost
*
+Rap+SH -6+Wi
Akt/p70s6k dependent signaling. Co-administration of inhibitors of RISK dependent
M)  and the mTOR/p70s6k inhibitor Rapamycin (Rap, 1 nM) abrogated the infarct
ars represent means ± S.E.M. N ≥ 7 in each group. *P < 0.001 vs. Ctr group.
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Fig. 3. Administration of BNP as a mimetic of postconditioning limits infarct size via
NPR. Blocking the natriuretic peptide receptor (NPR) with isatin (100 M) revoked
the  infarct-limiting effect of BNPPost. Infarct size is expressed as percentage of the
area at risk. Bars represent means ± S.E.M. N ≥ 7 in each group. *P < 0.001 vs. Ctr
group.
Table 1
Ratio of area at risk (AAR) and left ventricle (LV) volumes.
Group Inhibitor AAR/LV (%)
Ctr
No inhib 41.2 ± 3.4
Wi  43.7 ± 5.1
SH-6 48.6 ± 6.2
Rap 40.7 ± 5.8
Isatin 41.3 ± 2.6
BNPPost
No inhib 46.0 ± 3.8
Wi  35.4 ± 4.3
SH-6 45.2 ± 6.4
Rap 37.1 ± 1.9
Isatin 50.2 ± 3.7
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Fig. 4. Phosphorylation status of myocardial Akt in isolated hearts exposed to BNP
postconditioning. Representative immunoblots (top) and densinometric analysis
(bottom) of phosphorylated Akt (Ser473) in ex vivo rat hearts demonstrates that
BNPPost treatment resulted in a signiﬁcant increase in Akt (Ser473) phosphoryla-
tion as compared to the control group, while the Akt inhibitor SH-6 and the NPR
inhibitor isatin completely abolished it. Baseline BNP infusion (BNPB) did not sig-
niﬁcantly alter the degree of Akt phosphorylation as compared to control baseline
(CB). Densitometric analysis of total and phosphorylated Akt expressed in arbitrary
units (AU) where p-Akt are expressed as a ratio of total Akt with CB = 1. Bars represent
means ± S.E.M. N ≥ 3 in each group. *P < 0.001 vs. BNPPost, #P < 0.05 vs. BNPB, ¤P < 0.05
vs.  Ctr. Representative immunoblots of total and phosphorylated Akt (Ser473) (bot-
tom). GAPDH immunoblots indicate equal loading.
Fig. 5. Phosphorylation status of myocardial p70s6k in ex vivo hearts exposed to
BNP  postconditioning. Representative immunoblots (top) and densinometric anal-
ysis (bottom) of phosphorylated p70s6k (Thr389) in ex vivo rat hearts indicate that
BNPPost treatment signiﬁcantly increased p70s6k phosphorylation status at Thr389
as compared to the control group (Ctr). BNP infusion at baseline (BNPB) did not
alter p70s6k phosphorylation as compared to control baseline (CB). Densitomet-
ric analysis of total and phosphorylated p70s6k expressed in arbitrary units (AU)alues are mean ± S.E.M.
1 ± 2% vs. control 42 ± 4%, ns) (Fig. 2). In order to reveal the
nvolvement of cGMP/PKG signaling in BNPPost induced cardiopro-
ection, the non-speciﬁc NPR inhibitor isatin was co-administered
t immediate reperfusion. Isatin did not affect infarct size under
ontrol conditions (isatin 40 ± 3% vs. control 42 ± 4%, ns), but
ompletely abrogated the cardioprotection provided by BNPPost
BNPPost 17 ± 2% vs. BNPPost + isatin 46 ± 2%, p < 0.001) (Fig. 3). The
schemic risk zone constituted approximately 40–50% of the left
entricular muscle volume, and there were no signiﬁcant group
ifferences in the relative sizes of the AAR (volume of area at
isk/volume of left ventricle) (Table 1).
Baseline functional parameters were obtained after 18 min  of
tabilization. A signiﬁcant reduction in LVDP and CF after 5 min  of
egional ischemia conﬁrmed that all groups obtained similar and
xpected degrees of ischemia relative to corresponding stabiliza-
ion values (Table 2). Furthermore, there was no difference between
roups with regards to LVDP, CF and HR at 120 min  of reperfusion.
NP postconditioning phosphorylates Akt and p70s6k at early
eperfusion
Administration of BNP as a mimetic of ischemic postcondition-
ng (BNPPost) at early reperfusion resulted in a signiﬁcant increase in
kt phosphorylation compared to the control group (Fig. 4). Apply-
ng the Akt inhibitor SH-6 and the NPR inhibitor isatin abrogated
he BNPPost induced Akt phosphorylation (Fig. 4). The downstream
kt target p70s6k was also signiﬁcantly phosphorylated after BNP
ostconditioning compared to the control group (Fig. 5). BNP infu-
ion at baseline did not alter the phosphorylation status of Akt or
70s6k compared to corresponding baseline controls (Figs. 4 and 5).
where p-p70s6k are expressed as a ratio of total p70s6k with CB = 1. Bars repre-
sent means ± S.E.M. N ≥ 3 in each group. *P < 0.001 vs. BNPPost. GAPDH immunoblots
indicate equal loading.
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Table  2
Functional parameters recorded during the experimental protocol.
Group 18′ stab 5′ RI 30′ rep 120′ rep
LVDP
(mmHg)
Ctr 137 ± 7 70 ± 7* 84 ± 6* 59 ± 6*
Wi  134 ± 10 65 ± 7* 82 ± 6* 57 ± 5*
SH6 141 ± 9 71 ± 9* 61 ± 2* 44 ± 5*
Rap 126 ± 19 68 ± 7* 71 ± 3* 47 ± 5*
Isatin 148 ± 16 78 ± 9* 86 ± 11* 62 ± 6*
BNPPost 141 ± 10 84 ± 10* 85 ± 6* 63 ± 6*
BNPPost + Wi  122 ± 12 85 ± 13* 85 ± 15 56 ± 15*
BNPPost + SH6 142 ± 8 84 ± 12* 52 ± 4*,# 42 ± 4*
BNPPost + Rap 125 ± 12 87 ± 18* 90 ± 9* 61 ± 8*
BNPPost + Isatin 135 ± 6 70 ± 12* 76 ± 6* 47 ± 7*
CF
(ml/min)
Ctr 12 ± 2 7 ± 1* 10 ± 1 7 ± 1*
Wi  10 ± 1 6 ± 1* 8 ± 2 6 ± 1*
SH6 13 ± 1 8 ± 1* 9 ± 1* 7 ± 1*
Rap 11 ± 1 8 ± 1* 11 ± 1 8 ± 1*
Isatin 11 ± 1 7 ± 1* 8 ± 1* 7 ± 1*
BNPPost 12 ± 1 6 ± 1* 9 ± 1* 7 ± 1*
BNPPost + Wi  13 ± 1 8 ± 1* 12 ± 2 9 ± 2*
BNPPost + SH6 12 ± 1 7 ± 1* 7 ± 1* 7 ± 2*
BNPPost + Rap 11 ± 3 7 ± 1* 10 ± 3 8 ± 2*
BNPPost + Isatin 12 ± 1 7 ± 1* 8 ± 2 6 ± 1*
HR
(beats/min)
Ctr 259 ± 9 278 ± 12 294 ± 9 277 ± 10
Wi  265 ± 15 261 ± 16 243 ± 18 242 ± 22
SH6  294 ± 11 286 ± 14 253 ± 14 239 ± 17*
Rap 274 ± 17 257 ± 21 295 ± 8 271 ± 9
Isatin  282 ± 17 248 ± 14 248 ± 18 249 ± 17
BNPPost 267 ± 15 228 ± 22 238 ± 21 227 ± 19
BNPPost + Wi  285 ± 20 291 ± 24 278 ± 38 279 ± 22
BNPPost + SH6 289 ± 5 243 ± 50 235 ± 34# 199 ± 39
BNPPost + Rap 297 ± 27 266 ± 28 259 ± 48 275 ± 38
BNPPost + Isatin 280 ± 18 250 ± 22 229 ± 27 231 ± 25
Values represent mean ± S.E.M.
Ctr – ischemia reperfusion control; BNPPost – BNP postconditioning; Wi  – 15 min Wortmannin (1 M) at reperfusion; SH6 – 15 min SH-6 (10 M)  at reperfusion; Rap – 15 min
o n.
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* P < 0.05 vs. corresponding stab.
# P < 0.05 vs. Ctr.
he level of total Akt, total p70s6k and loading control GAPDH did
ot alter between the groups.
NP mRNA levels at early reperfusion in the area at risk of
nfarction is regulated by Akt dependent signaling
Myocardial BNP mRNA levels in area at risk (AA) were signif-
cantly elevated at early reperfusion (15 min) as compared to the
on-ischemic myocardium (ANA, area not at risk) (Ctr(AA) 2.7 ± 0.5
s. Ctr(ANA) 1.2 ± 0.2, p < 0.05) (Fig. 6A). Furthermore, the ventricu-
ar BNP expression in AA at 15 min  of reperfusion was signiﬁcantly
p-regulated as compared to the ischemic control (0 min  reper-
usion) (Ctr(AA) 2.7 ± 0.5 vs. ischemia 1.0 ± 0.1, p < 0.05), while there
ere no differences between ANA and the ischemic control (Ctr(ANA)
.2 ± 0.2 vs. ischemia 1.0 ± 0.1, ns) (Fig. 6A). The ventricular BNP
xpression levels in AA returned to ischemic levels after 120 min
f reperfusion (Ctr(AA) 1.2 ± 0.3 vs. ischemia 1.0 ± 0.1, ns), and with
o differences in expression levels between AA and ANA (Ctr(AA)
.2 ± 0.3 vs. Ctr(ANA) 0.9 ± 0.3, ns). These results imply that the
eperfusion process ampliﬁes BNP expression in the area at risk
s compared to the ischemic group and the remote non-ischemic
art of the myocardium at early reperfusion.
In separate experiments, we also investigated the effect of
schemic postconditioning (IPost) and Akt inhibition on BNP mRNA
xpression at early reperfusion in the area at risk of infarction.
yocardial BNP mRNA was signiﬁcantly up-regulated in ischemic
ostconditioned (IPost) hearts as compared to ischemic controls
t early reperfusion (IPost 6.7 ± 1.3 vs. ischemia 1.0 ± 0.2, p < 0.05)
Fig. 6B). BNP expression in the parallel run controls were also ele-
ated (Ctr 5.4 ± 0.8 vs. ischemia 1.0 ± 0.2, p < 0.05). Furthermore,
nhibiting Akt with SH-6 completely abrogated the elevated BNPmRNA expression levels both in the IPost and control group (IPost
6.7 ± 1.3 vs. IPost + SH-6 1.8 ± 0.7, p < 0.05) (Ctr 5.4 ± 0.8 vs. SH-6
1.5 ± 0.9, p < 0.05) (Fig. 6B), indicating that Akt may  modulate BNP
expression levels at early reperfusion.
Discussion
The ﬁndings can be summarized as follows: (1) when exogenous
B-type natriuretic peptide (BNP) was  intermittently infused for
3 × 30 s, in a postconditioning like fashion (BNPPost), it signiﬁcantly
reduced infarct size in the ex vivo rat heart. (2) BNPPost cardiopro-
tection was  abolished by inhibiting PI3K/Akt/p70s6k dependent
signaling and by inhibition of natriuretic peptide receptors using
isatin. (3) Pharmacological postconditioning with BNP peptides ele-
vated Akt and p70s6k phosphorylation at early reperfusion. (4) The
myocardial BNP mRNA levels in the area at risk (AA) were signiﬁ-
cantly elevated at early reperfusion compared to ischemic control
tissue and remote ANA (area not at risk). (5) Ischemic postcondi-
tioning (IPost) did not elevate the BNP mRNA levels beyond the
control group at early reperfusion. (6) Inhibition of Akt abrogated
the early reperfusion induced BNP mRNA expression levels.
It has previously been shown that exogenous administration of
BNP prior to, during and immediately after coronary occlusion pro-
tects the heart against ischemia reperfusion induced injury [9–13]
via a cGMP/PKG driven mechanism [11], regulating the opening of
intracellular KATP-channels [9,29]. It is well known that the RISK
member Akt serves as a focal point for signal transduction path-
ways coding for cell survival [30] and Akt mediated signaling events
has been associated with activation of cGMP and PKG [31]. In the
current study, we show that intermittent pharmacological manip-
ulation of the heart for 3 × 30 s with BNP at early reperfusion, in
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 postconditioning like fashion (BNPPost), reduced infarct size in
solated rat hearts. This BNPPost induced cardioprotection was lost
hen inhibiting the classical RISK-kinases; PI3K with wortman-
in, Akt with SH-6 and p70s6k with rapamycin. BNPPost treatment
lso enhanced the phosphorylation of Akt and p70s6k. In addition,
nhibition of Akt with SH-6 at reperfusion completely blunted BNP
nduced Akt phosphorylation. Our ﬁndings are in accordance with
revious studies where BNP treatment during reperfusion have
een found to activate both Akt and PKC in isolated mouse hearts
10], when administrated at hypoxia-reoxygenation to neonatal rat
ardiomyocytes to prevented opening of the mitochondrial perme-
bility pore (mPTP), partly via PI3K/Akt dependent signaling [32].
dministration of ANP infusion just prior to reperfusion also acti-
ated the RISK members PI3K and ERK in isolated perfused rabbit
earts [16].
Natriuretic peptides (NPs) interact with three types of mem-
rane natriuretic peptide receptors (NPR) A, B and C. BNP has been
hown to activate both NPR-A and C [15]. The density of NPR-C in
ost tissue is higher than that of NPR-A/B, and NPR-C has a high
fﬁnity for BNP [33]. Several studies have reported that NPs recruit
he PI3/Akt signaling pathway via NPR-C [33,34]. Thus, cGMP/PKG
nd RISK signaling could be the result of BNP binding to two  differ-
nt receptors; cGMP is produced when BNP binds NPR-A and RISK
ignaling activated when BNP binds the NPR-C [9,33]. In this study,
he BNPPost induced cardioprotection and Akt phosphorylation was
ompletely abolished by the non-selective NP receptor inhibitor
satin. At the concentration applied in this study (100 M),  isatin
as been shown to inhibit both particulate guanylyl cyclase activa-
ion via the NPR-A receptor, and also the NPR-C receptor (reviewed
n [35]). Unfortunately, other non-peptide speciﬁc antagonists of
PRs are currently not available, and we are therefore unable to
onclude which NPR that conveys the RISK mediated cardioprotec-
ion by BNPPost.
Acute myocardial ischemia (AMI) up-regulates BNP gene
xpression in cardiac ventricles [7,8], but lately it has been sug-
ested that ischemia-reperfusion (IR) may  serve as an independent
rigger of increased BNP mRNA myocardial content [19]. Our results
ndicate that reperfusion per se stimulates BNP mRNA expression
eyond the ischemia induced expression level in the area at risk
AA). No regulation was evident in the remote non-ischemic area
ANA) at the same time point, and within 120 min  of reperfusion was  normalized to GAPDH and expressed in arbitrary units (AU). Bars represent
the BNP expression levels had returned to ischemic levels, with no
difference between the AA and ANA. These results are in accor-
dance with the results of Ramos et al. [19], who  found that the
BNP mRNA level was increased in the IR region (AA) as compared
to the non-ischemic area (ANA) of the isolated rat heart indepen-
dent of changes in the ventricular function. Seen in conjunction
with our study, this implies that early reperfusion induced mod-
ulation of BNP gene expression is restricted to the ischemic area,
reinforcing the concept of temporal molecular changes in the IR
myocardium (AA) at very early reperfusion as compared to the
remote myocardium (ANA).
In addition to being a marker of AMI  and heart failure, Burley
et al. speculated that NPs may  be autacoid mediators of ischemic
postconditioning (IPost), since the unspeciﬁc NPR-A/-C inhibitor
isatin abolished the IPost induced protection [9]. Our results show
that IPost does not inﬂuence BNP mRNA expression levels in the
area at risk beyond the control group at early reperfusion. Despite
comparable mRNA expression levels in IPost and control, it may
not be representative for the BNP content/activity or the amount of
BNP released from the myocardium. However, Goetze et al. found
that plasma BNP and proBNP concentrations most likely reﬂected
an increase in BNP gene expression in the ischemic human left
ventricle, since the concentration were closely associated with ven-
tricular mRNA expression [36].
Accumulation of nucleus activated Akt promote cardiomy-
ocytes survival [37] via phosphorylation of multiple protein
substrates and gene transcription regulation [20–23]. Nucleus tar-
geted Akt has also been shown to promote ANP expression via
an autocrine/paracrine stimulated PI3K-dependent signaling cas-
cade [38]. Our results indicate that inhibition of Akt using SH-6 has
the ability to depress left ventricular BNP mRNA expression. This
implies that Akt-dependent signaling may  be involved in regulat-
ing cardiac BNP expression at early reperfusion. Further studies are
warranted to fully delineate the role of Akt in IR induced regula-
tion of cardiac BNP mRNA levels, and to further evaluate whether
the shift in gene expression is transitional or if it has long-term
functional implications.Several studies have documented a correlation between the
plasma BNP concentration and infarct size in patients suffering
from acute myocardial infarction (AMI) [7,39,40]. Normally, plasma
BNP concentrations lie between 0 and 10 pmol/L, and circulating
ptides
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evels may  increase several 100-folds during AMI [39]. Interest-
ngly, Hillock et al. observed that a 60 h exogenous BNP infusion
0.01 g/kg/min) induced an incremental plasma BNP concentra-
ion within the range observed in severe MI  and heart failure, but
ithout reporting any safety hazard such as symptomatic hypoten-
ion, renal function or mortality [41]. Similarly, BNP infusion
0.05 g/kg/min) for 4 h in an acute AMI  pig model were well tol-
rated post-MI, with a peak plasma concentration of 1003 pmol/L
42]. We  applied short and cyclic 3 × 30 s infusion of BNP (10 nM)
t early reperfusion, leading to a total administration time of only
.5 min. The applied dose is in the supra-physiological range, but
nly 10 times higher than the peak plasma BNP concentration mea-
ured post-MI in the study of Kousholt et al. [42]. Hence, it is clear
hat the optimal concentration, timing and duration of BNP infu-
ion after MI  should be addressed in future studies, acknowledging
hat higher BNP dosages may  have several serious side effects in
ivo [43].
In conclusion, BNP administered in a postconditioning like
anner reduced infarct size in the ex vivo rat heart. This cardiopro-
ection is mediated via PI3K/Akt/p70s6k dependent RISK signaling,
ut further investigation is needed to elucidate the speciﬁc contri-
ution of NPR-A vs. NPR-C. The data also indicate that Akt signaling
ay  participate in regulation of BNP mRNA expression at early
eperfusion.
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